| Market Capitalization (Millions $) |
2,003 |
| Shares
Outstanding (Millions) |
66 |
| Employees |
365 |
| Revenues (TTM) (Millions $) |
1,246 |
| Net Income (TTM) (Millions $) |
359 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Galapagos NV is a biotechnology company headquartered in Mechelen, Belgium with additional offices and research facilities in the United States and Europe. The company was founded in 1999 by Onno van de Stolpe, Rudi Pauwels, and Katrine Bosley, and has since grown into a major player in the development of innovative medicines based on new biological insights.
Galapagos NV specializes in the discovery and development of small molecule and antibody drugs designed to treat inflammatory and fibrotic diseases, as well as cancer. The company is focused on developing drugs that target specific biological pathways and mechanisms, including protein kinases, G-protein-coupled receptors, and fibroblast growth factors.
Galapagos NV operates through three main business units: Research, Development, and Services. The Research unit focuses on drug discovery, using innovative screening techniques and collaboration with academic and industry partners to identify new drug targets and lead compounds. The Development unit manages clinical trials and regulatory approval of new drugs, while the Services unit provides contract research and development services to third-party clients.
The company's pipeline includes several promising drug candidates in various stages of development. These include filgotinib, a selective JAK1 inhibitor currently in phase 3 trials for rheumatoid arthritis, Crohn's disease, and other inflammatory diseases; ziritaxestat (GLPG1690), an autotaxin inhibitor in phase 3 trials for idiopathic pulmonary fibrosis; and MOR106, an anti-IL-17 antibody in phase 2 trials for atopic dermatitis.
Galapagos NV is also known for its proprietary drug discovery platform, which incorporates genetics, chemistry, and biology to identify new drug targets and lead compounds. The company's platform includes several technologies, including target discovery, drug screening, and target validation, as well as a large and diverse library of compounds for drug optimization.
In addition to its drug discovery efforts, Galapagos NV is committed to sustainability and environmental stewardship. The company has implemented several initiatives to reduce its carbon footprint and operate in an environmentally responsible manner, including the use of renewable energy in its facilities and support for biodiversity conservation initiatives in the Galapagos Islands.
Overall, Galapagos NV is a leading biotechnology company that is dedicated to innovative drug development and sustainability. With its strong pipeline of drug candidates, proprietary drug discovery platform, and commitment to environmental responsibility, the company is well-positioned to continue to make important contributions to the healthcare and biotechnology industries.
Company Address: Generaal De Wittelaan L11 A3 Mechelen 2800
Company Phone Number: Stock Exchange / Ticker: NASDAQ GLPG
|
0.79% 
97.2 %